NATIONAL BUREAU OF ECONOMIC RESEARCH
NATIONAL BUREAU OF ECONOMIC RESEARCH

Hedonic Analysis of Arthritis Drugs

Iain M. Cockburn, Aslam H. Anis

NBER Working Paper No. 6574
Issued in May 1998
NBER Program(s):   PR

We examine the relationship between quality'' and market outcomes for a group of drugs used to treat rheumatoid arthritis. Though this is a widespread and debilitating disease with very substantial impacts on the health of patients and on the economy, currently available drugs have limited efficacy and serious side effects. Clinical research conducted since these products were approved has resulted in substantial revisions to the body of scientific information available to physicians. The relative quality' of these drugs (as captured by efficacy and toxicity measurements reported in peer-reviewed clinical trials) has changed markedly over the past 15 years. Yet in our analysis of US wholesale prices we find that relative prices appear to be only weakly related to quality. We do however find a relationship between changes in reported efficacy and toxicity and the evolution of quantity shares in this market.

download in pdf format
   (1041 K)

email paper

This paper is available as PDF (1041 K) or via email.

Machine-readable bibliographic record - MARC, RIS, BibTeX

Published: Hedonic Analysis of Arthritis Drugs, Iain M. Cockburn, Aslam H. Anis, in Medical Care Output and Productivity (2001), University of Chicago Press (p. 439 - 462)

Users who downloaded this paper also downloaded these:
Cockburn and Anis Hedonic Analysis of Arthritis Drugs
Berndt, Cutler, Frank, Griliches, and Newhouse w6817 Price Indexes for Medical Care Goods and Services: An Overview of Measurement Issues
 
Publications
Activities
Meetings
Data
People
About

Support
National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email: info@nber.org

Contact Us